OptimizeRX (OPRX) PT Raised to Street High $70 at Roth Capital

Roth Capital analyst Richard Baldry raised the price target on OptimizeRX (NASDAQ: OPRX) to Street High $70.00 (from $40.00) while maintaining a Buy rating.

The analyst comments "Given its RFP pipeline doubled yr/yr in 3Q20, we believe OPRX could accelerate organic growth to 100% in 2020. Instead of increasing our 2021 forecasts, we are introducing a 2022 forecast that we view as a fair guidepost for 2021's potential upside. Given we expect both material upside to current forecasts, OPRX is our 2021 Top Pick. We are increasing our PT to $70 ($40 prior) by using our new 4Q22 forecast (4Q21 prior) as the basis for our target."

You May Also Be Interested In

• Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
• Moderna (MRNA) PT Raised to $89 at Morgan Stanley
• Wolverine World Wide (WWW) PT Raised to $20 at Williams Trading